Search

Your search keyword '"José R. Mercado-Matos"' showing total 2 results
Start Over Author "José R. Mercado-Matos"
2 results on '"José R. Mercado-Matos"'

1. Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

Author

Shigeru Kawabata, José R. Mercado-Matos, M. Christine Hollander, Danielle Donahue, Willie Wilson III, Lucia Regales, Mohit Butaney, William Pao, Kwok-Kin Wong, Pasi A. Jänne, and Phillip A. Dennis

Subjects
Biology (General), QH301-705.5
Abstract

Lung cancer in never-smokers is an important disease often characterized by mutations in epidermal growth factor receptor (EGFR), yet risk reduction measures and effective chemopreventive strategies have not been established. We identify mammalian target of rapamycin (mTOR) as potentially valuable target for EGFR mutant lung cancer. mTOR is activated in human lung cancers with EGFR mutations, and this increases with acquisition of T790M mutation. In a mouse model of EGFR mutant lung cancer, mTOR activation is an early event. As a single agent, the mTOR inhibitor rapamycin prevents tumor development, prolongs overall survival, and improves outcomes after treatment with an irreversible EGFR tyrosine kinase inhibitor (TKI). These studies support clinical testing of mTOR inhibitors in order to prevent the development and progression of EGFR mutant lung cancers.

Published
2014
Full Text
View/download PDF

2. Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

Author

Willie Wilson, Lucia Regales, Shigeru Kawabata, William Pao, Pasi A. Jänne, Mohit Butaney, Danielle R. Donahue, M. Christine Hollander, José R. Mercado-Matos, Phillip A. Dennis, and Kwok-Kin Wong

Subjects
Lung Neoplasms, Molecular Sequence Data, Mutant, Article, General Biochemistry, Genetics and Molecular Biology, Mice, Random Allocation, T790M, medicine, Animals, Humans, Epidermal growth factor receptor, Lung cancer, lcsh:QH301-705.5, PI3K/AKT/mTOR pathway, Sirolimus, Antibiotics, Antineoplastic, biology, TOR Serine-Threonine Kinases, RPTOR, medicine.disease, 3. Good health, respiratory tract diseases, ErbB Receptors, lcsh:Biology (General), Drug Resistance, Neoplasm, Mutation, Immunology, Disease Progression, Cancer research, biology.protein, medicine.drug
Abstract

SummaryLung cancer in never-smokers is an important disease often characterized by mutations in epidermal growth factor receptor (EGFR), yet risk reduction measures and effective chemopreventive strategies have not been established. We identify mammalian target of rapamycin (mTOR) as potentially valuable target for EGFR mutant lung cancer. mTOR is activated in human lung cancers with EGFR mutations, and this increases with acquisition of T790M mutation. In a mouse model of EGFR mutant lung cancer, mTOR activation is an early event. As a single agent, the mTOR inhibitor rapamycin prevents tumor development, prolongs overall survival, and improves outcomes after treatment with an irreversible EGFR tyrosine kinase inhibitor (TKI). These studies support clinical testing of mTOR inhibitors in order to prevent the development and progression of EGFR mutant lung cancers.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results